Effects of Pioglitazone in Congenital Adrenal Hyperplasia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Congenital adrenal hyperplasia, an autosomal recessive condition, is mainly caused by
mutations in the gene 21-hydroxylase and is treated with glucocorticoids in a slightly
supraphysiological dose. Adult patients seem to be characterized by insulin resistance, which
may be caused by the glucocorticoids and/or the accompanying obesity. The hypothesis of this
study is that pioglitazone can improve insulin sensitivity and correlated cardiovascular risk
factors in this specific group of patients. This will be tested in a randomized,
placebo-controlled, cross-over trial; insulin sensitivity will be quantified by euglycemic
hyperinsulinemic clamp studies.